FindTrial
Sign In

Effect of modified Yiqi Huoxue therapy on patients with heart failure with preserved ejection fraction

Effect of modified Yiqi Huoxue therapy on patients with heart failure with preserved ejection fraction

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100046951
Enrollment
Unknown
Registered
2021-06-01
Start date
2018-11-01
Completion date
Unknown
Last updated
2022-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure with preserved Ejection Fraction,HFpEF

Interventions

Treatment group:modified Yiqi Huoxue therapy combined with conventional western medicine treatment
Control group:conventional western medicine treatment

Sponsors

Beijing Hepingli Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The diagnosis of HFPEF was based on the 2018 Guidelines for the Diagnosis and Treatment of Chronic Heart Failure in China. Main diagnostic criteria: 1. Symptoms: dyspnea, fatigue, edema of lower limbs; 2. Signs: rales in the lungs, tachypnea, swollen jugular vein, enlarged liver; 3. Auxiliary examination: echocardiography revealed enlarged heart, abnormal cardiac function, and elevated plasma levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP). However, the Left Ventricle Eject Fraction (LVEF) >= 50%.

Exclusion criteria

Exclusion criteria: Patients with hyperthyroidism, renal disease, tumor, recent urinary tract infection, short-term systemic infection, and pregnancy.

Design outcomes

Primary

MeasureTime frame
heart rate;blood pressure;Left Atrial Diameter, LAD;Left Ventricular End-diastolic Dimension, LVEDD;E/A;6 Minute Walk Distance, 6MWD;—

Countries

China

Contacts

Public ContactWang Yu

Beijing Hepingli hospital

rongxuewuhen000@126.com+86 13671182721

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026